Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Researchers have created an AI tool to accelerate the development of new disease treatments and demonstrated its potential by identifying an existing drug with the potential to prevent deadly heart ...

Affecting 1 in 500 people, hypertrophic cardiomyopathy is a condition in which the walls of the left ventricle, the heart's ...

Discover the life-extending approaches to managing heart failure through medication adherence, lifestyle modifications, and ...

Researchers have shed new light on how a type of heart valve disease -- aortic valve stenosis -- progresses differently in males and females.

Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ...

Mouth taping may help reduce mouth breathing during sleep. Learn this practice's possible benefits and risks and what the ...

Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...

While several effective treatment options for AFib exist, current evidence strongly suggests that pulsed field ablation (PFA) ...

While it’s well-known that issues like high blood pressure, diabetes, smoking and not enough exercise are risk factors for a ...

About 10% of Americans say they have chronic insomnia, and millions of others report poor sleep quality. Ongoing research has ...